Key result
SGLT-2i lead new pediatric heart failure prescriptions at ~53%, predominantly for post-Fontan patients.
Why the study?
New heart failure drug prescriptions by Japanese pediatric cardiologists were not previously investigated at a nationwide level.
What are the prescription patterns of new heart failure drugs by pediatric cardiologists in Japan?
Cross-Sectional (n=357)
Yes
What are the prescription patterns of new heart failure drugs by pediatric cardiologists in Japan?
This nationwide survey highlights the real-world use of new heart failure medications like SGLT-2i and ARNI in pediatric and congenital heart disease patients, underscoring the urgent need for pediatric-specific clinical trials and guidelines.
Answers are grounded in this paper and cite their sources.
May inform emerging off-label preferences in pediatric HF; leaves open efficacy, safety, and guideline development pending dedicated trials.
Background: This nationwide survey investigated new heart failure drug prescriptions by Japanese pediatric cardiologists. Methods and Results: Among 97 responding institutions, 357 patients received sodium-glucose cotransporter-2 inhibitors (SGLT-2i; n=189), angiotensin receptor-neprilysin inhibitors (ARNI; n=89), selective hyperpolarization-activated cyclic nucleotide-gated channel (HCN) blockers (n=76), or soluble guanylate cyclase (sGC) stimulators (n=3). SGLT-2i were predominantly prescribed in post-Fontan patients (45%), with one-third being children under 18 years. ARNI were commonly used for biventricular congenital heart disease (CHD) and cardiomyopathy (47% and 29%), with 40% under 18 years. Conclusions: Pediatric-specific clinical trials and appropriate usage guidelines are urgently needed.
No takes yet. Share an insight, caveat, or question.
Muneuchi et al. (2026) conducted a cross-sectional in Pediatric heart failure (n=357). New heart failure drugs (SGLT-2i, ARNI, HCN blockers, sGC stimulators) was evaluated on Prescription frequency of new heart failure drugs. Among 357 patients prescribed new heart failure drugs by Japanese pediatric cardiologists, SGLT-2i were the most frequently prescribed, predominantly for post-Fontan univentricular congenital heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: